INTRODUCTION
Subjects were treated with oral artemether-lumefantrine (AL; Coartem) administered over three consecutive days, a standard of care for P. falciparum malaria in Kenya. The first dose was observed by the study team and remaining doses were self-administered at home. Subjects living near study centers were asked to return on Day 7, for repeat malaria testing.
In vitro drug sensitivity testing. A SYBR Green I-based in vitro IC 50 drug sensitivity assay, described earlier, 6, 7, 9 was used to test each P. falciparum field isolate against a panel of six conventional antimalarials supplied as chloroquine diphosphate (CQ), mefloquine hydrochloride (MQ), quinine sulfate hydrate (QN), artemisinin (AR), amodiaquine hydrochloride (AQ), and doxycycline hyclate (DX). Because all test drugs, except AR (pure base), were provided as a salt and prepared by weight:volume convention, we used salt formulation weights (except AR) to calculate IC 50 values. Test drugs, except DX, were obtained from Walter Reed Army Institute of Research, (Silver Spring, MD). DX was obtained commercially (Sigma-Aldrich, Co., St. Louis, MO; catalog number D9891). Anti-folate drugs were omitted because P. falciparum resistance in Kenya is established. 15, 18, 19 Reference P. falciparum clones assayed periodically for internal control against all six drugs included D6, considered CQ-sensitive and MQ-resistant (CQ-S; MQ-R) and W2, considered CQ-resistant and MQ-sensitive (CQ-R; MQ-S), as well as AR-sensitive. 5 Quinine sulfate hydrate generally parallels CQ for D6 and W2 IC 50 trends. 7 The D6 and W2 clones were obtained from frozen stocks and culture adapted for SYBR Green I IC 50 assays.
To prepare test drugs, stock drug solutions at 1 mg/mL were prepared in 5 mL 70% ethanol for MQ and QN or 100% dimethyl sulfoxide for AR, AQ, and DX. For CQ, 1.5 mL deionized water was combined with 3.5 mL of absolute ethanol. Further dilutions were in complete RPMI 1640 media to the desired starting concentration, followed by serial 2-fold dilutions to generate 10 concentrations for IC 50 testing. 17 The concentration ranges (ng/mL), from highest to lowest, were CQ (1,000 to 1.953), MQ (250 to 0.488), QN (2,000 to 3.906), AR (100 to 0.195), AQ (100 to 0.195), and DX (50,000 to 97.656). The drug solutions were prepared and used immediately, or stored at −80°C for not longer than 1 month before use. Basic and complete RPMI 1640 culture media, the latter with glucose and hypoxanthine enrichment, were prepared as described.
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Plasmodium falciparum field isolates refrigerated in transport media, and the two P. falciparum laboratory reference clones D6 and W2, were culture adapted before IC 50 SYBR Green I assay. The parasites were cultured at 6% hematocrit for 7-30 days, to reach 3-8% parasitemia. 5 For IC 50 drug assays, culture-adapted parasites were adjusted to 2% hematocrit and 1% parasitemia, and antimalarial drug aliquots in complete RPMI 1640 and added to the wells as described below.
Plasmodium falciparum isolates processed IEV were placed into assay within 6 hours of phlebotomy, without culture adaptation. Blood samples with > 1% parasitemia were adjusted to 1% parasitemia at 2% hematocrit, and those with ≤ 1% parasitemia were used unadjusted at 2% hematocrit.
For culture-adapted and IEV assays, transfer of parasite sample and antimalarial drug aliquots in complete RPMI 1640 drug aliquots onto 96-well microculture plates and addition of lysis buffer after 72 hours incubation was done as previously described. 7 The plates were then placed at room temperature in the dark, for 5-15 minutes. Parasite replication inhibition was quantified and the IC 50 for each drug calculated by an equation generating a sigmoidal concentration-response curve (variable slope), with log transformed drug concentrations on the X axis and relative fluorescent units (RFUs) on the Y axis (Graphpad Prism for Windows, version 4.0; Graphpad Software, Inc., San Diego, CA). 6, 7 Assessing possible sources of SYBR Green I background signal. In experiment set 1, to measure the intrinsic effect of each drug alone on SYBR Green I RFU, in comparison with complete assay wells, we plated each drug over the standard 10 dilutions in complete RPMI 1640 media alone ("drug only" wells), or in complete RPMI 1640 media containing 1% P. falciparum parasitemia and 32,000 peripheral blood mononuclear cells (PBMC)/well ("complete assay" wells), respectively. The PBMC were isolated by density gradient from the blood of a healthy donor. Drug only and 1 set of complete assay wells were processed without incubation, and a second set of complete assay wells were incubated for 72 hours at 37°C in a gas mixture, described earlier. 7 All plates were then processed for SYBR Green I RFU measurements by Genios Tecan. For complete assay wells, 32,000 PBMC/well approximated the number of white blood cells (WBC) in a typical IEV well, based on an estimate of 8,000 WBC/uL of whole blood in a subject. We also assessed a range of P. falciparum parasitemias, from 1% to 0.112% (2-fold dilutions), to determine the capability of SYBR Green I to discern IC 50 s in IEV samples with low parasitemias.
In experiment set 2, to assess the influence of PBMC concentration on SYBR Green I assay RFU, we plated a range of PBMC (61 to 250,000 cells/well) in complete RPMI 1640 media with 1% P. falciparum parasitemia, without incubation, and then measured RFUs within 15 minutes by Genios Tecan. All experiments were conducted in triplicate.
Pfmdr1 copy number. Plasmodium falciparum DNA for all molecular assays was extracted from FTA filter paper blots or whole blood using QIAamp DNA Blood Mini Kit (Qiagen, Inc., Alameda, CA), according to manufacturer instructions.
The 2 −DDCt method of relative quantification was used to estimate P. falciparum multiple drug resistance gene 1 ( Pfmdr1 ) copy numbers. 20 For this method, there should be at least 1 calibrator with a known number of copies of the gene under study, and a housekeeping gene with constant copy number to normalize the quantitative data. 21 For the calibrator, we used genomic DNA from P. falciparum reference clone 3D7, known to have 1 copy of Pfmdr1 gene. 21 Plasmodium falciparum tubulin served as a housekeeping gene, and Dd2 P. falciparum clone DNA served as a Pfmdr1 multiple copy control.
The relative quantification of the Pfmdr1 gene was determined as previously described. 20 Briefly,
, where x is the field isolate and y is 3D7. The results were then calculated as n -fold changes in P. falciparum isolate Pfmdr1 gene copies, normalized to P. falciparum tubulin, relative to the copy number of Pfmdr1 in P. falciparum 3D7 using the equation 2 −DDCt , as described. 20, 21 Each sample was run in triplicate and the Ct value of each well recorded at the end of the reaction. The average of the Ct values for each sample was used for the determination of Pfmdr1 copy number.
Pfmdr1 codon single nucleotide polymorphism (SNP) analysis. SNP analysis was conducted for Pfmdr1 codons 86 (N86Y), 184 (Y184F), 1034 (S1034C), and 1042 (N1042D) using realtime polymerase chain reaction (PCR). 22, 23 Probes consisted of VIC for wild-type and 6-FAM (6-carboxyfluoroscein) for the mutation. 23 Plasmodium falciparum reference clones 3D7 (MQ-S) and Dd2 (MQ-R), as well as D6 and W2, were also assayed.
RESULTS

Subject enrollment and follow up.
Three hundred fifty-two P. falciparum RDT (+) subjects provided blood samples. For Day 7 post-treatment appointments, 216 subjects tested by Parascreen remained PfHRP-2 (+), but were pLDH (−), the latter indicating absence of P. falciparum. All blood smears were (−) for P. falciparum asexual stages; five had gametocytes.
SYBR Green I IC 50 drug assays. We assayed 121 P. falciparum field isolates, 91 IEV, and 30 culture-adapted, against a panel of six drugs. A "successful" assay, defined as a concentration-response across the 10 drug concentrations for 1 or more drugs per each P. falciparum field isolate, occurred in 68% of all isolates. For IEV, the success rate for all assays was 70%, 78% with parasitemias > 0.5% and 61% for parasitemias ≤ 0.5%. For culture adaptation, 63% of the assays were successful. Figure 2A -F shows individual and median IC 50 s for IEV and culture-adapted P. falciparum field isolates, against each of the six drugs, along with D6 (CQ-S, MQ-R) and W2 (CQ-R, MQ-S) P. falciparum reference clones. For CQ, QN, AQ, and DX median IC 50 values for IEV versus culture-adapted P. falciparum field isolates were similar ( P ≥ 0.05, Mann-Whitney rank sum test). For MQ and AR, median IC 50 values of culture-adapted P. falciparum isolates were higher than IEV isolates ( P < 0.05, Mann-Whitney rank sum test), at 1.8-and 1.5-fold, respectively. The IC 50 ranges for all drugs, except AR, were generally larger for IEV than culture-adapted P. falciparum isolates in the upper half of the IC 50 range.
For all drugs, except AR, SYBR Green I median IC 50 s for IEV and culture-adapted P. falciparum isolates were similar to historical median IC 50 s from 3 H-hypoxanthine uptake assays on culture-adapted P. falciparum isolates collected in Kenya from 1997 to 2002 ( Figure 2A-F ) . 17 The AR median IC 50 values for SYBR Green I IEV and culture-adapted P. falciparum isolates were about 2-to 4-fold higher than the earlier 3 H-hypoxanthine assays, respectively. SYBR Green I background RFU experiments. Experiments are summarized in Figure 3A -C . In Figure 3A (Group 1), drug + media versus complete assay wells (drug + 1% parasitemia + 32,000 PBMC/well), both without incubation, showed a difference of about 1,000 RFU for each drug, with little overlap. Media alone values were similar to drug + media. These observations implied that none of the drugs, at any concentration, would obscure IC 50 readouts. Complete assay wells with no incubation (Group 2) versus with incubation for 72 hours at 37°C (Group 3; akin to IC 50 P. falciparum drug assays), the latter median RFU values were ~2-fold higher, indicative of parasite replication.
In Figure 3B , drug concentrations used in the IC 50 assays generated sigmoidal curves, indicating 50% parasite replication inhibition at about 4,000 RFU. Data from Figure 3A and other experiments (not shown) indicated background RFU signal (drug + medium + 32 K PBMC) subtracted from the RFU value of each IC 50 replicate was unnecessary, consistent with earlier work. 6 Finally, SYBR Green I assay discerned IC 50 s for complete assay wells with P. falciparum parasitemias ranging from 1% to 0.112%, against all six test drugs (data not shown). These observations, and Figure 3B , are relevant to IEV processing.
In Figure 3C , to determine the RFU signal of PBMC plated across a wide concentration range in complete assays wells (+1% P. falciparum parasitemia), RFU values for wells with ≤ 30,000 PBMC were about 2,500 RFU, a value that would not be expected to obscure the identification of drug IC 50 values, at about 4,000 RFU.
Molecular assays of P. falciparum samples. Plasmodium falciparum field isolates ( N = 308) had a mean Pfmdr1 gene copy number of 1, quantified relative to the P. falciparum reference clones 3D7, with a mean of 1 copy, and multiple drug-resistant Dd2 clone, with a mean of 3.5 copies.
The mutation (86Y) rates in Pfmdr1 codons were highest at codon 86 (66%), with fewer at codons 184 (38%) and 1034 (12%), and none at codon 1042, regardless of the collection site. The SNP rates at the four codons were similar among the four locations where P. falciparum isolates were collected, including lowland versus highland sites. As in earlier work, mutant and mixed (mutant + wild) genotypes were combined to depict total mutant genotype populations. 17 Associations between the Pfmdr1 codon 86 SNPs and CQ, MQ, and AR IC 50 values are shown in Figure 4A -C. Plasmodium falciparum field isolates with Pfmdr1 codon 86 mutation (86Y) (66% of isolates) had a higher median CQ IC 50 (lower CQ sensitivity), in comparison with Pfmdr1 codon 86 wild (N86) samples. For MQ and AR, P. falciparum isolates with Pfmdr1 codon 86Y had a lower median IC 50 , in comparison with Pfmdr1 codon 86 wild, both statistically significant ( P < 0.05).
DISCUSSION
This is the first report from Kenya describing a SYBR Green I assay for measuring in vitro drug IC 50 s against P. falciparum field isolates. Notably, SYBR Green I assay was conducted at our field-based laboratory, proximal to P. falciparum collection sites, using six drugs. Several earlier reports describe SYBR Green I assays in developed countries, assessing P. falciparum clones against a few drugs.
7, 9 Second, we assayed P. falciparum field isolates IEV and by culture adaptation, obtaining IC 50 values in 70% and 63% of assays, respectively. These success rates, higher than historical radioisotope uptake assays in our laboratory, may reflect simpler processing. The overall expedience of SYBR Green I supports continued use.
Median IC 50 s in SYBR Green I assays for each of six drugs, among IEV and culture-adapted samples, generally paralleled our earlier data using 3 H-hypoxanthine uptake in Figure 2 . ( A -F ) SYBR Green I drug IC 50 s for Plasmodium falciparum field isolates, shown as scatter plot and median (red bar). IC 50 ranges of P. falciparum reference clones D6 and W2 for chloroquine diphosphate (CQ), mefloquine hydrochloride (MQ), and quinine sulfate hydrate (QN) shown in two hatched boxes; for artemisinin (AR), amodiaquine hydrochloride (AQ), and doxycycline hyclate (DX), in single hatched box. Purple bars: median IC 50 in P. falciparum field isolates obtained 1997-2002 (culture-adapted, radioisotope uptake assay). 17 Black lines on CQ, MQ, and QN graphs: IC 50 threshold values considered discriminative for "resistant" P. falciparum isolates (culture-adapted, radioisotope uptake assay).
culture-adapted P. falciparum isolates. 17 For example, about 30% of CQ IC 50 s and 50% of MQ IC 50 s in SYBR Green I assays exceeded previously established in vitro discriminative "resistance" values of 45 ng/mL and 10 ng/mL, respectively. 17 The IC 50 ranges for two P. falciparum reference clones, D6 and W2, paralleled their expected CQ and MQ sensitivity profiles. These observations underscored adaptability of the SYBR Green I IC 50 assay to a field-based laboratory.
We processed P. falciparum field isolates IEV or culture adapted, depending on proximity to the laboratory. For P. falciparum isolates stored for several days at 4°C, we waited until parasitemias reached 3-8% before drug IC 50 testing. Here, IEV was feasible because of laboratory proximity to two collection sites, with P. falciparum isolates placed into assay soon after collection. Encouragingly, against each of four drugs (CQ, QN, AQ, DX), median IC 50 s of IEV and culture-adapted isolates were similar, differing only for MQ and AR, at 1.5-and 1.8-fold, respectively, albeit relatively low magnitudes for IC 50 testing. The IEV was simpler than culture adaptation, as others observed. 6 To partly address background concerns for SYBR Green I assay, we confirmed each drug alone did not affect RFU values. Second, complete RPMI 1640 media with 1% P. falciparum and 32,000 PBMC/well, approximating WBC in an IEV assay well, appeared unlikely to elevate RFUs to a level obscuring IC 50 interpretations. Finally, relevant to IEV, we found that SYBR Green I assay discerns drug IC 50 s with P. falciparum parasitemias as low as 0.112%, an issue in debate. Among IEV assays, the upper half of IC 50 ranges was notably higher for five drugs, in comparison with culture adaptation. This might reflect greater biological variability in IEV P. falciparum isolates, including better preserved sub-populations of drug-resistant and sensitive parasites. 11, 25, 26 It may be useful to determine multiplicity of infection of each P. falciparum isolate, processed IEV, and culture adapted, along with comparative IEV and culture-adapted SYBR Green I assays.
AR was the lone drug without larger IEV IC 50 ranges, in comparison with culture-adapted isolates, perhaps because there are few, if any, AR-resistant clones in Kenya. Alternatively, this may reflect the activity of AR against most P. falciparum blood stages. 27 Median IC 50 values for AR, among IEV and culture-adapted assays, were 2-to 3-fold higher in comparison with earlier radioisotope assays, and a recent report of SYBR Green I assessing freeze-thawed, culture-adapted P. falciparum samples. 7, 17 Higher AR IC50s are unlikely to represent resistance, but perhaps methodological variability.
The SYBR Green I IC 50 values for six drugs, establishing a modest baseline for western Kenya, support continued work to better define IC 50 s. For radioisotope assays using cultureadapted P. falciparum isolates, IC 50 values discriminative for in vivo "resistance" exist (CQ, MQ, QN, and five others). 17 If SYBR Green I is widely implemented for in vitro P. falciparum drug testing, reference IC 50 values discriminative for resistance, ideally linked with in vivo responses, could enhance usefulness.
In Kenya, with artemether + lumefantrine (Coartem) implemented as the artemisinin combination therapy (ACT ) standard in 2003, and with no clinical evidence of resistance, there is an opportunity with SYBR Green I assay to track A+ L IC 50 values. Indeed, in East Africa, Kenya is often a sentinel site for drug resistance. 15, 28 As such, we have developed SYBR Green I assays for artemether, lumefantrine, artemisinin combinations, as well as atovaquone, halofantrine, primaquine, and tafenoquine.
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Pfmdr1 is a constitutive gene in P. falciparum that confers multiple drug resistance when more than 1 copy is present. 2 Parasites with multiple Pfmdr1 copies are most common in Southeast Asia, where multiple drug-resistant P. falciparum malaria, including MQ, exists. 2, 29, 30 As expected, our P. falciparum field isolates from western Kenya contained an average of 1 copy number of Pfmdr1 , 31 consistent with a wild-type genotype not necessarily associated with multidrug resistance. 32 MQ has not been widely used in Kenya, precluding comment on in vitro MQ IC 50 s and in vivo responsiveness.
SNPs in certain Pfmdr1 codons may confer drug resistance. [32] [33] [34] Among P. falciparum isolates we collected earlier (1997) (1998) (1999) (2000) (2001) (2002) , Pfmdr1 codon 86 mutation (86Y) rates in two western sites (Kisumu, Kericho) were 35% and 68%, respectively (mean, 51%), whereas two eastern sites (Entosopia, Magadi) had rates > 85%. 17 This reflected CQ resistance in Kenya. 17, 35 Here, in P. falciparum isolates from western Kenya, mutation rates in codon 86 were 66%, far less at 184 and 1,034. The mutation rates in codons 86, 184, and 1034 were similar for lowland and highland sites, suggesting Pfmdr1 SNPs are not necessarily associated with severe malaria presentation, often anemia and cerebral malaria, respectively. 36 We interpret the similarity in Pfmdr1 codon 86 mutation (86Y) rates for 1997-2002 (51%) and this study (66%), along with similar CQ IC 50 s, as sustained CQ resistance in Kenya. 14, 17, 37 Indeed, most P. falciparum isolates contained codon 86 mutation (86Y), modestly associated with higher CQ IC 50 s. Mutation in pfcrt , well established in Kenya, also confers CQ resistance. In contrast, Pfmdr1 codon 86 mutations (86Y) were associated with lower median IC 50 s for MQ, and AR. This parallels earlier reports describing Pfmdr1 codon 86Y and drug IC 50 relationships, typically direct with CQ, and inverse with MQ. 38 For AR, a lower median IC 50 in P. falciparum field isolates expressing Pfmdr1 codon 86 mutation (86Y) supports the notion this mutation is unlikely associated with emerging AR resistance. 39, 40 Received November 29, 2010. Accepted for publication February 11, 2011. 
